Related Experiment Video
Updated: Jan 8, 2026

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation
Published on: October 31, 2019
Designing at-source and end-of-pipe biotechnologies to tackle pharmaceutical pollution
Vladimir Akhrimenko1, Klaus Kümmerer2, Sixto Malato3
1Basque Sustainable Pharmacy and Biotherapy Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain.
Abstract:
Pharmaceutical pollution, defined as the presence of antibiotics, antidepressants, antidiabetics, and other pharmaceuticals in the environment, is a ubiquitous problem. Active pharmaceutical ingredients (APIs), along with their metabolites and excipients, pose a threat to public health, biodiversity, and ecosystems. In response to this environmental challenge, European legislation has been updated to include certain APIs as priority pollutants and to require the installation of advanced wastewater treatment facilities capable of eliminating them. To deliver an effective response to pharmaceutical pollution, we believe it is essential to implement a combination of at-source and end-of-pipe solutions. In addition, cutting-edge biotechnological tools such as gene engineering, omics analysis, biosensors, and microfluidics have yet to realize their full potential in tackling pharmaceutical pollution.
More Related Videos
Related Concept Videos
Bioremediation
Environmental Applications of Microorganisms
Biological Methods for Microbial Control
Drug Biotransformation: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

